Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.

Bauwens, Deborah;Maerevoet, Marie;Michaux, Lucienne;Théate, Ivan;Van Den Neste, Eric;et.al.
(2005) British Journal of Haematology — Vol. 131, n° 3, p. 338-340 (2005)

Files

25826.pdf
  • Restricted Access
  • Adobe PDF
  • 60.79 KB
Request a copy

Details

Authors
Show more
Abstract
We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bauwens, D., Maerevoet, M., Michaux, L., Théate, I., Hagemeijer, A., Stul, M., Danse, E., Costantini, S., Vannuffel, P., Straetmans, N., Vekemans, M.-C., Deneys, V., Ferrant, A., & Van Den Neste, E. (2005). Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. British Journal of Haematology, 131(3), 338-340. https://doi.org/10.1111/j.1365-2141.2005.05777.x (Original work published 2005)